LabCorp reported a strong Q1 with 5.8% revenue growth and 30bps margin expansion, raising full-year revenue and EPS guidance. Management highlighted double-digit growth in specialty testing (oncology, neurology) and a robust pipeline of hospital/regional lab acquisitions, while noting manageable headwinds from weather and fuel costs. Q1 revenue grew 5.8% to $3.5B, with adjusted EPS of $4.25, up 10.6%.
Buzzberg readRaising guidance midpoints for revenue and EPSLabCorp reported a strong Q1 with 5.8% revenue growth and 30bps margin expansion, raising full-year revenue and EPS guidance. Management highlighted double-digit growth in specialty testing (oncology, neurology) and a robust pipeline of hospital/regional lab acquisitions, while noting manageable headwinds from weather and fuel costs. Q1 revenue grew 5.8% to $3.5B, with adjusted EPS of $4.25, up 10.6%.Read full analysisCollapse analysis
LabCorp reported a strong Q1 with 5.8% revenue growth and 30bps margin expansion, raising full-year revenue and EPS guidance. Management highlighted double-digit growth in specialty testing (oncology, neurology) and a robust pipeline of hospital/regional lab acquisitions, while noting manageable headwinds from weather and fuel costs. Q1 revenue grew 5.8% to $3.5B, with adjusted EPS of $4.25, up 10.6%.
Full-year EPS guidance raised by 13 cents to $17.70-$18.35, revenue midpoint up $30M.
Diagnostics volume growth was 1.1% organic, held back by ~$15M weather impact; price/mix rose 2.6%.
BLS organic constant-currency revenue grew 3.7% with strongest momentum in central labs (up 4.9% organically).
BLS revenue$0.781B
reported
DIAGNOSTICS revenue$2.8B
reported
Revenue$3.5376B
+1% QoQ
EPS$4.25
+4% QoQ
What changed this quarter
01
Guidance
Raising guidance midpoints for revenue and EPS
Guidance · revenue to $13.5B
02
Demand
Central labs grow 11%, organic constant currency 5%
Management expressed confidence in momentum, raised guidance midpoints, and highlighted strong growth in specialty areas and pipeline activity.
03
Demand
BLS trailing 12-month book-to-bill healthy at 1.04
Central labs grow 11%, organic constant currency 5%. Management expressed confidence in momentum, raised guidance midpoints, and highlighted strong growth in specialty areas and pipeline activity.
04
Macro
CRUSH initiative supported but cautioned for unintended consequences
Diagnostics volume growth was 1.1% organic, held back by ~$15M weather impact; price/mix rose 2.6%.
AI, capex & demand read
AI
Platform & monetization
Management discussed expanding AI use in digital pathology, real-world data for Alzheimer's research, and operational efficiencies via collaborations with PathAI, AWS/DataVant, and Optimum AI, aiming to improve customer experience and reduce costs.
Demand
Bookings & conversion
Central labs grow 11%, organic constant currency 5%. Management expressed confidence in momentum, raised guidance midpoints, and highlighted strong growth in specialty areas and pipeline activity.
Capex
Investment and capacity
Capital expenditures are expected to be approximately 4% of revenue, with investment in a new strategic facility to support long-term growth in central lab services.
Tone · Upbeat
Management expressed confidence in momentum, raised guidance midpoints, and highlighted strong growth in specialty areas and pipeline activity.
Supply-chain alpha
A1
LabCorp estimates Q1 weather impact was $15 million, reducing organic volume growth from ~2% to 1.1%, with a limited recapture of lost volume from physician offices.
“we estimated it was about a $15 million impact for the quarter. ... organic volume growth would have been approximately 2% if it wasn't for the impact of weather.”
Fuel price increases from April are expected to have only a $5-10 million AOI impact for 2026, reflecting the company's hedging and hybrid fleet strategy.
“if you just look at the fuel prices in early April, the estimated AOI impact is approximately $5 to $10 million this year. We believe this impact is manageable”
BLS segment book-to-bill was weaker (0.94) in Q1 due to timing shifts from Q4 and into Q2, but management projects it will rise above 1.0 for the rest of the year on strong CLS RFP momentum.
“that's based upon the .94 being mostly driven by timing, some that fell into fourth quarter versus first quarter, some that fell from first quarter into second quarter.”
Management expects the pipeline of hospital and regional lab deals to strengthen if PAMA goes into effect in January, as smaller labs will struggle to compete with scale players like LabCorp.
“if PAMA is implemented in January, although there will be a short-term impact during the year to us, I think over time it actually will increase the pipeline of deals because these local regional laboratories are under a lot of stress alre…”
LabCorp is expanding its oncology testing reach via partnership with Illumina, potentially driving more sequencing volume onto Illumina's platforms in community settings.
“As part of our growth in specialty areas, we collaborated with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings.”
… market. In neurology, we experience double-digit growth driven by a market-leading portfolio in Alzheimer's testing. Oncology also achieved double-digit growth, supported by the launch of several liquid biopsy tests, and expanded access to MRD solutions over the past year. Additionally, when providers choose LabCorp for specialty testing, we see them consolidating a greater share of their patients' testing needs with LabCorp. As part of our growth in specialty areas, we collaborated with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings. We expanded nationwide access to the first FDA-approved companion diagnostics that helps identify platinum-resistant ovarian cancer patients who may benefit from Merck's Keytruda, which can reduce the risk of disease progression and improve overall survival. In addition to these specialty areas, we continue to increase our portfolio with tests that address pressing clinical needs. Recently, we launched the LabCorp Fentanyl Urine Visual Test an FDA-cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours. Moving to …
… operational efficiency and productivity. Our recent progress includes an expansion of our collaboration with PathAI to deploy an FDA-cleared digital pathology platform across our national anatomic pathology labs and hospital laboratory collaboration. This platform embeds AI into everyday clinical decision-making by enabling pathologists to review and manage cases digitally, improve turnaround times, and increase consistency of results. A new AI-powered real-world data platform being developed in partnership with Amazon Web Services and DataVant to accelerate Alzheimer's research. By combining Agenic AI with LabCorp's diagnostic and real-world data, the goal is to improve patient recruitment for clinical trials and ultimately shorten drug development timelines. A strategic collaboration with Optimum AI to apply AI capabilities to streamline laboratory operations, improve efficiency, and enhance the patient and provider experience. providing clearer insights to patients about their health, test progress, and next steps in care. For physicians, it'll help in ordering clinically appropriate tests upfront, reduce administration delays, and speed patient access to results. This work …
LabCorp's companion diagnostic supports wider use of Keytruda in a newly approved indication, potentially benefiting Merck's drug sales.
“We expanded nationwide access to the first FDA-approved companion diagnostics that helps identify platinum-resistant ovarian cancer patients who may benefit from Merck's Keytruda”
… the launch of several liquid biopsy tests, and expanded access to MRD solutions over the past year. Additionally, when providers choose LabCorp for specialty testing, we see them consolidating a greater share of their patients' testing needs with LabCorp. As part of our growth in specialty areas, we collaborated with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings. We expanded nationwide access to the first FDA-approved companion diagnostics that helps identify platinum-resistant ovarian cancer patients who may benefit from Merck's Keytruda, which can reduce the risk of disease progression and improve overall survival. In addition to these specialty areas, we continue to increase our portfolio with tests that address pressing clinical needs. Recently, we launched the LabCorp Fentanyl Urine Visual Test an FDA-cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours. Moving to consumer health, where we continue to deliver double-digit growth, LabCorp OnDemand launched new tests in the quarter for insulin resistance and pancreatic function. We also …
Management expects the pipeline of hospital and regional lab deals to strengthen if PAMA goes into effect in January, as smaller labs will struggle to compete with scale players like LabCorp. — PAMA implementation could accelerate consolidation in the lab industry, benefiting large-scale players like LabCorp and Quest Diagnostics.
Good morning, Erin. Good morning. So how would you describe the deal pipeline right now? Like, what are you seeing in terms of the pipeline, both in terms of acquisitions as well as partnerships, outreach deals, otherwise? Like, given just the landscape that we're in, the uncertainties and seeing, you know, are you seeing an acceleration or building pipeline of these types of deals with health systems or otherwise? And how does it maybe compare to this time last year? Thanks.
Yeah, thanks for the question. Our pipeline remains very strong. And I wouldn't say it's accelerated versus this time last year. It was strong this time last year. I've spent quite a bit of time talking with different folks in health systems across the country. And I think you're right. They are struggling right now. And they are looking for ways to partner and for ways for us to work with them. And I don't think that is going to stop anytime soon. In fact, if PAMA is implemented in January, although there will be a short-term impact during the year to us, I think over time it actually will increase the pipeline of deals because these local regional laboratories are under a lot of stress already. These hospital system laboratories are under stress already, and I think that would just make it more difficult. So stay tuned. I expect we'll have some more deals that we'll be talking about in the future, and I look forward to talking about those.
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.